Prognostic value of lactate dehydrogenase expression in different cancers: a meta-analysis
Jiancheng Lv,Zijian Zhou,Jingzi Wang,Hao Yu,Hongcheng Lu,Baorui Yuan,Jie Han,Rui Zhou,Xiaolei Zhang,Xiao Yang,Haiwei Yang,Pengchao Li,Qiang Lu
DOI: https://doi.org/10.1016/j.amjms.2019.09.012
IF: 3.462
2019-01-01
The American Journal of the Medical Sciences
Abstract:Background: This meta-analysis was performed to elucidate the association between the expression of lactate dehydrogenase (LDH) and the prognosis of various malignant neoplasms. Materials and Methods: Qualified studies were systematically identified from relevant databases, including PubMed, Cochrane Library, Embase, WanFang, and HowNet. A total of 17 eligible studies with 4,176 patients that complied with the inclusion criteria were enrolled in this meta-analysis. The 17 articles were published from 2011 to 2018. The hazard ratio (HR) and 95% confidence interval (95%CI) were obtained from the selected studies. Results: The analysis that included all LDH-related studies showed a significant association with the overall survival (OS) outcome (HR = 1.74, P = 0.001) but exhibited an insignificant association with the disease-free survival (DFS) or recurrence-free survival (RFS) outcome (HR = 1.40, P = 0.072). High lactate dehydrogenase A (LDHA) expression was significantly relevant to inferior OS (HR = 1.88, 95%CI: 1.37-2.59) and DFS or RFS (HR = 1.56, 95%CI: 1.29-1.89). Conclusions: High LDH expression and the prognostic outcome of various cancer patients are significantly correlated. High LDHA expression is a promising biomarker for forecasting the survival of patients and the recurrence of different cancers in these patients. Further associative studies are required due to the complex role of LDH genes.